# Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia

> **NCT00588146** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 10 (actual)

## Conditions studied

- Anemia
- Liver Disease
- Hypoxemia

## Interventions

- **DRUG:** Pegylated Interferon Alpha2b
- **OTHER:** Standard care

## Key facts

- **NCT ID:** NCT00588146
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Schering-Plough discontinued supplying study drug.
- **Last updated:** 2013-02-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00588146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00588146, "Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00588146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*